Browse MAP2K3

Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00069 Protein kinase domain
Function

Dual specificity kinase. Is activated by cytokines and environmental stress in vivo. Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in the MAP kinase p38. Part of a signaling cascade that begins with the activation of the adrenergic receptor ADRA1B and leads to the activation of MAPK14.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0032147 activation of protein kinase activity
GO:0033674 positive regulation of kinase activity
GO:0035897 proteolysis in other organism
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0044033 multi-organism metabolic process
GO:0045860 positive regulation of protein kinase activity
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004708 MAP kinase kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0004713 protein tyrosine kinase activity
GO:0005057 receptor signaling protein activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04015 Rap1 signaling pathway
hsa04620 Toll-like receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04668 TNF signaling pathway
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04912 GnRH signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-1643685: Disease
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168249: Innate Immune System
R-HSA-450294: MAP kinase activation in TLR cascade
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-5339562: Uptake and actions of bacterial toxins
R-HSA-5210891: Uptake and function of anthrax toxins
R-HSA-450302: activated TAK1 mediates p38 MAPK activation
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAP2K3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAP2K3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 3.56; FDR: 0.048 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAP2K3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1910.532
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0240.992
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3560.821
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0370.917
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3030.88
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4690.857
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0780.838
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1790.9
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0340.984
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5560.725
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7680.743
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1090.158
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAP2K3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAP2K3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAP2K3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAP2K3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAP2K3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAP2K3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAP2K3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAP2K3
Namemitogen-activated protein kinase kinase 3
Aliases MEK3; MKK3; MAPKK3; MAPK/ERK kinase 3; MAP kinase kinase 3; dual specificity mitogen activated protein kinas ......
Chromosomal Location17q11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAP2K3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.